ModMed ranks #1 in all 11 of its specialty-specific EHR systems in 2024 Black Book Survey
Health IT company takes home top rankings for specialty-specific EHRs in allergy and OBGYN for the first timeBOCA RATON, Fla.--(BUSINESS...
Month: February 2024
Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
CitiusTech Launches Healthcare’s First End-to-End Generative AI Quality & Trust Solution
PRINCETON, N.J.--(BUSINESS WIRE)--#CitiusTech--CitiusTech, a leading provider of healthcare technology services and solutions, announced that it has launched an industry-first solution...
CitiusTech Launches Healthcare’s First End-to-End Generative AI Quality & Trust Solution
PRINCETON, N.J.--(BUSINESS WIRE)--#CitiusTech--CitiusTech, a leading provider of healthcare technology services and solutions, announced that it has launched an industry-first solution...
New Missouri Rural Health Program Directs Resources to Rural Communities to Improve Social Care Outcomes
The Missouri HealthNet Division introduces a new care model that utilizes the Unite Us Payments solution to create sustainability for...
New Missouri Rural Health Program Directs Resources to Rural Communities to Improve Social Care Outcomes
The Missouri HealthNet Division introduces a new care model that utilizes the Unite Us Payments solution to create sustainability for...
Scryb Announces Development of New Enterprise AI Venture
Toronto, Ontario--(Newsfile Corp. - February 14, 2024) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company") is pleased...
Unveiling Fortifeye Rejuvenate Collagen
A Groundbreaking Formula for Health and VitalityOCALA, FL / ACCESSWIRE / February 14, 2024 / Fortifeye Vitamins, a leading provider...
Unveiling Fortifeye Rejuvenate Collagen
A Groundbreaking Formula for Health and VitalityOCALA, FL / ACCESSWIRE / February 14, 2024 / Fortifeye Vitamins, a leading provider...
Skinvisible Announces Significant Progress in Licensee’s Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising...
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that...
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by...
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data...
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and...
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase...
Evoke Pharma Announces Closing of $7.5 Million Public Offering
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in FullSOLANA BEACH, Calif., Feb. 14, 2024...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel...